trial

Goal Management Training for Patients With Schizophrenia or High Risk for Schizophrenia

NCTId NCT03048695
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 83 (actual)
Sponsored by Sykehuset Innlandet HF
Primary completion 2020-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
83 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2017-05-18
Primary completion
2020-12-31
Eligibility
ALL · 16 Years · 67 Years

Interventions & indications

Drugs
GMT

Sponsors

Sykehuset Innlandet HFLead Sponsor
University of OsloCollaborator

Investigators

1
Merete G Øie, PhdPrincipal Investigator

Sites

1 total
Reinsvoll, Norway

Facts & assertions

4 sourced
Enrollment
83
Phase
NA
Primary Completion Date
2020-12-31
Status
COMPLETED
relationships
The graph out of here
drug
GMT
drug
lead_sponsor
Sykehuset Innlandet HF
company
collaborator
University of Oslo
company
indication
Schizophrenia
indication
Neurocognitive Disorders
indication
Schizophrenia
indication
investigator
Merete G Øie, Phd
person